Lercanidipinhydrochlorid Doc

Lercanidipine hydrochloride, the active ingredient in Lercanidipinhydrochlorid Doc, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Lercanidipinhydrochlorid Doc as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage high blood pressure and related cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack. Isolated systolic hypertension: improves arterial compliance and controls elevated systolic pressure. Primary (essential) hypertension: provides long‑term blood‑pressure control as part of antihypertensive therapy.

Lercanidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, usually on the face or neck. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway. - Life‑threatening arrhythmias: ventricular tachycardia or fibrillation.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor blood pressure: adjust dose based on response and avoid excessive hypotension. Assess liver function: use with caution in patients with hepatic impairment. Caution in the elderly: start at low dose due to increased sensitivity. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. Use with caution in heart‑failure patients: monitor for fluid retention. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines that affect its metabolism or blood‑pressure‑lowering effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Concomitant use with other potent antihypertensives: risk of additive hypotension. - Grapefruit juice: can raise drug concentration.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: monitor for combined heart‑rate effects. - NSAIDs: may blunt antihypertensive response. - Statins metabolised by CYP3A4: watch for increased statin levels.